X4 Pharmaceuticals Future Growth

Future criteria checks 2/6

X4 Pharmaceuticals is forecast to grow earnings and revenue by 3.8% and 63.9% per annum respectively while EPS is expected to grow by 13.1% per annum.

Key information

3.8%

Earnings growth rate

13.1%

EPS growth rate

Biotechs earnings growth	27.5%
Revenue growth rate	63.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	19 Dec 2024

Recent future growth updates

Recent updates

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Earnings and Revenue Growth Forecasts

NasdaqCM:XFOR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	62	-107	-97	N/A	5
12/31/2025	17	-139	N/A	N/A	6
12/31/2024	2	-32	N/A	N/A	6
9/30/2024	1	-17	-133	-126	N/A
6/30/2024	1	18	-120	-112	N/A
3/31/2024	N/A	-129	-104	-104	N/A
12/31/2023	N/A	-101	-97	-97	N/A
9/30/2023	N/A	-111	-88	-88	N/A
6/30/2023	N/A	-131	-86	-86	N/A
3/31/2023	N/A	-96	-83	-83	N/A
12/31/2022	N/A	-96	-77	-77	N/A
9/30/2022	N/A	-103	-77	-77	N/A
6/30/2022	N/A	-102	-72	-72	N/A
3/31/2022	N/A	-100	-73	-73	N/A
12/31/2021	N/A	-103	-72	-71	N/A
9/30/2021	N/A	-85	-70	-69	N/A
6/30/2021	N/A	-82	-71	-69	N/A
3/31/2021	N/A	-78	-63	-62	N/A
12/31/2020	3	-62	-60	-59	N/A
9/30/2020	3	-55	-52	-51	N/A
6/30/2020	3	-55	-50	-49	N/A
3/31/2020	3	-53	-53	-52	N/A
12/31/2019	N/A	-53	-48	-48	N/A
9/30/2019	N/A	-55	-46	-46	N/A
6/30/2019	N/A	-46	-40	-39	N/A
3/31/2019	N/A	-40	-31	-31	N/A
12/31/2018	N/A	-36	-25	-25	N/A
9/30/2018	N/A	-31	-23	-23	N/A
12/31/2017	N/A	-25	N/A	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XFOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XFOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XFOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XFOR's revenue (63.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: XFOR's revenue (63.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XFOR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 02:51
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Leah Rush Cann	Brookline Capital Markets
Arlinda Lee	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.

X4 Pharmaceuticals Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 8.9% to US$3.68

Consensus revenue estimates increase by 12%

Price target increased by 8.7% to US$3.55

Price target increased by 13% to US$3.65

Price target decreased by 8.9% to US$3.20

Price target increased by 7.5% to US$3.76

Recent updates

New major risk - Financial position

Price target decreased by 8.9% to US$3.68

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

CEO, President & Director notifies of intention to sell stock

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

New major risk - Revenue and earnings growth

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Consensus revenue estimates increase by 12%

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

Price target increased by 8.7% to US$3.55

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Price target increased by 13% to US$3.65

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 8.9% to US$3.20

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

CFO, Treasurer & Corporate Secretary notifies of intention to sell stock

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Director recently sold US$138k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target increased by 7.5% to US$3.76

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Price target decreased by 9.5% to US$4.07

Price target decreased by 12% to US$4.21

Consensus revenue estimates fall by 11%

Price target decreased to US$5.08

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Price target increased to US$5.90

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals: Upcoming Catalysts

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Price target decreased to US$12.36

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$13.57

Consensus forecasts updated

Price target decreased to US$15.43

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

Price target decreased to US$18.00

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

Founder notifies of intention to sell stock

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Founder notifies of intention to sell stock

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

Founder notifies of intention to sell stock